adenocarcinoma

Summary

Summary: A malignant epithelial tumor with a glandular organization.

Top Publications

  1. doi Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
  2. doi Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
  3. pmc Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
    Marcin Imielinski
    Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA
    Cell 150:1107-20. 2012
  4. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
  5. pmc International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 6:244-85. 2011
  6. doi Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    Lecia V Sequist
    Lecia V Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA James Chih Hsin Yang, National Taiwan University Hospital Chun Ming Tsai, Taipei Veterans General Hospital, Taipei Wu Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan Kenneth O Byrne, St James Hospital, Dublin, Ireland Vera Hirsh, McGill University, Montreal, Quebec, Canada Tony Mok, Prince of Wales Hospital, Hong Kong, China Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand Sergey Orlov, Pavlov State Medical University, St Petersburg Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia Jaafar Bennouna, Institut de Cancérologie de l Ouest site René Gauducheau, Nantes, France Ki Hyeong Lee, Chungbuk National University Hospital
    J Clin Oncol 31:3327-34. 2013
  7. doi FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
  8. pmc Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    Shinichi Yachida
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nature 467:1114-7. 2010
  9. ncbi Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
  10. pmc Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
    Kerby Shedden
    Department of Statistics, 1085 South University, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nat Med 14:822-7. 2008

Detail Information

Publications375 found, 100 shown here

  1. doi Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
    ..Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer...
  2. doi Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
    ....
  3. pmc Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
    Marcin Imielinski
    Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA
    Cell 150:1107-20. 2012
    Lung adenocarcinoma, the most common subtype of non-small cell lung cancer, is responsible for more than 500,000 deaths per year worldwide. Here, we report exome and genome sequences of 183 lung adenocarcinoma tumor/normal DNA pairs...
  4. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
    ..However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown...
  5. pmc International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Thorac Oncol 6:244-85. 2011
    b>Adenocarcinoma is the most common histologic type of lung cancer...
  6. doi Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    Lecia V Sequist
    Lecia V Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA James Chih Hsin Yang, National Taiwan University Hospital Chun Ming Tsai, Taipei Veterans General Hospital, Taipei Wu Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan Kenneth O Byrne, St James Hospital, Dublin, Ireland Vera Hirsh, McGill University, Montreal, Quebec, Canada Tony Mok, Prince of Wales Hospital, Hong Kong, China Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand Sergey Orlov, Pavlov State Medical University, St Petersburg Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia Jaafar Bennouna, Institut de Cancérologie de l Ouest site René Gauducheau, Nantes, France Ki Hyeong Lee, Chungbuk National University Hospital
    J Clin Oncol 31:3327-34. 2013
    ..A phase II study of afatinib in EGFR mutation-positive lung adenocarcinoma demonstrated high response rates and progression-free survival (PFS).
  7. doi FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
    Thierry Conroy
    Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France
    N Engl J Med 364:1817-25. 2011
    ....
  8. pmc Distant metastasis occurs late during the genetic evolution of pancreatic cancer
    Shinichi Yachida
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nature 467:1114-7. 2010
    ..These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease...
  9. ncbi Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
    David Cunningham
    Department of Medicine, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 355:11-20. 2006
    ..fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma. We assessed whether the addition of a perioperative regimen of ECF to surgery improves outcomes among ..
  10. pmc Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
    Kerby Shedden
    Department of Statistics, 1085 South University, University of Michigan, Ann Arbor, Michigan 48109, USA
    Nat Med 14:822-7. 2008
    ..This study also provides the largest available set of microarray data with extensive pathological and clinical annotation for lung adenocarcinomas...
  11. pmc Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma
    Paolo P Provenzano
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Cancer Cell 21:418-29. 2012
    ..In combination with the standard chemotherapeutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently achieves objective tumor responses, resulting in a near doubling of overall survival...
  12. ncbi Papillomaviruses and cancer: from basic studies to clinical application
    Harald zur Hausen
    Deutsches Krebsforschungszentrum, Heidelberg, Germany
    Nat Rev Cancer 2:342-50. 2002
    ..Epidemiological studies have underlined that HPVs are the main aetiological factor for cervical cancer. But how has this knowledge been translated into the clinic to allow the prevention, screening and treatment of cervical cancer?..
  13. ncbi Esophageal cancer
    Peter C Enzinger
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 349:2241-52. 2003
  14. pmc Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
    Julian R Molina
    Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:584-94. 2008
    ..Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, ..
  15. ncbi Epidemiologic classification of human papillomavirus types associated with cervical cancer
    Nubia Munoz
    International Agency for Research on Cancer, Lyons, France
    N Engl J Med 348:518-27. 2003
    ..Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but the risk associated with the various HPV types has not been adequately assessed...
  16. doi Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial
    Sean M McBride
    Harvard Radiation Oncology Program, Harvard University, 100 Blossom Street, 3, Boston, MA 02114, USA
    Cancer 118:3681-90. 2012
    Recent reports using extreme hypofractionated regimens in the treatment of low-risk prostate adenocarcinoma have been encouraging...
  17. ncbi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
    Hisayuki Shigematsu
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Natl Cancer Inst 97:339-46. 2005
    ..However, the role of such mutations in the pathogenesis of lung cancers is unclear...
  18. doi American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
    Carmen J Allegra
    Division of Hematology Oncology, Department of Medicine, University of Florida Shands CancerCenter, Gainesville, FL, USA
    J Clin Oncol 27:2091-6. 2009
    ....
  19. ncbi Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
    Nozomu Yanaihara
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Cell 9:189-98. 2006
    ..These results indicate that miRNA expression profiles are diagnostic and prognostic markers of lung cancer...
  20. pmc Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma
    Jingchun Jin
    Department of Pathology, YanBian University Medical College, Yanji City, Jilin Province, PR China
    Diagn Pathol 7:135. 2012
    ..It has been suggested that Ezrin expression plays an important role in tumor metastasis. This study is aimed to investigate the clinicopathological significance of Ezrin overexpression in gastric adenocarcinomas...
  21. pmc Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
    Austin M Dulak
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 45:478-86. 2013
    The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ~15%, the identification of new therapeutic targets for EAC is greatly important...
  22. pmc Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity
    L Vermeulen
    Laboratory for Experimental Oncology and Radiobiology, Center for Experimental Molecular Medicine, Academic Medical Center, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:13427-32. 2008
    ..Single-cell-cloned CSCs can form an adenocarcinoma on xenotransplantation but do not generate the stroma within these tumors...
  23. pmc KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e17. 2005
    ..Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive...
  24. pmc Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
    Sarah P Thayer
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nature 425:851-6. 2003
    ..Here we report that sonic hedgehog, a secreted hedgehog ligand, is abnormally expressed in pancreatic adenocarcinoma and its precursor lesions: pancreatic intraepithelial neoplasia (PanIN)...
  25. ncbi Identification of pancreatic cancer stem cells
    Chenwei Li
    Department of Surgery, University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Cancer Res 67:1030-7. 2007
    ....
  26. pmc WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis
    Don X Nguyen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cell 138:51-62. 2009
    Metastasis from lung adenocarcinoma can occur swiftly to multiple organs within months of diagnosis. The mechanisms that confer this rapid metastatic capacity to lung tumors are unknown...
  27. doi A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese
    Zhibin Hu
    Department of Epidemiology and Biostatistics, Ministry of Education MOE Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China
    Nat Genet 43:792-6. 2011
    ..12 and 22q12.2) were newly identified in the Chinese population. These results suggest that genetic variants in 3q28, 5p15.33, 13q12.12 and 22q12.2 may contribute to the susceptibility of lung cancer in Han Chinese...
  28. doi Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis
    Li Liu
    Department of Epidemiology and Biostatistics and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
    Carcinogenesis 32:336-42. 2011
    Single genetic variation may only have a modest effect on risk of gastric cardia adenocarcinoma (GCA) because this malignancy is believed to result from complex interactions among multiple genetic and environmental factors...
  29. pmc Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
    William W Lockwood
    Cancer Biology and Genetics Section, Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 109:19408-13. 2012
    ..To test this hypothesis, we treated a panel of lung adenocarcinoma (LAC) cell lines with the BET inhibitor JQ1 and found that a subset is acutely susceptible to BET inhibition...
  30. pmc Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation
    Matthew D Wilkerson
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS ONE 7:e36530. 2012
    Lung adenocarcinoma (LAD) has extreme genetic variation among patients, which is currently not well understood, limiting progress in therapy development and research...
  31. pmc The transcriptional landscape and mutational profile of lung adenocarcinoma
    Jeong Sun Seo
    Genomic Medicine Institute GMI, Medical Research Center, Seoul National University, Seoul 110 799, Korea
    Genome Res 22:2109-19. 2012
    ..Here we present the first large scale RNA sequencing study of lung adenocarcinoma, demonstrating its power to identify somatic point mutations as well as transcriptional variants such as gene ..
  32. ncbi Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
    A V D'Amico
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, Mass 02215, USA
    JAMA 280:969-74. 1998
    Interstitial radiation (implant) therapy is used to treat clinically localized adenocarcinoma of the prostate, but how it compares with other treatments is not known.
  33. ncbi Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
    Udaya K Liyanage
    Alvin J Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    J Immunol 169:2756-61. 2002
    ..These T(reg) may mitigate the immune response against cancer, and may partly explain the poor immune response against tumor Ags...
  34. ncbi Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer
    E Kapiteijn
    Department of Surgery, Leiden University Medical Center, The Netherlands
    N Engl J Med 345:638-46. 2001
    ..2 percent in the surgery-only group (P<0.001). CONCLUSIONS: Short-term preoperative radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a standardized total mesorectal excision...
  35. ncbi The new World Health Organization classification of lung tumours
    E Brambilla
    Service de Pathologie Cellulaire, Centre Hospitalier Universitaire de Grenoble, France
    Eur Respir J 18:1059-68. 2001
    ..Another change is the subclassification of adenocarcinoma: the definition of bronchioalveolar carcinoma has been restricted to noninvasive tumours...
  36. ncbi Genetic clonal diversity predicts progression to esophageal adenocarcinoma
    Carlo C Maley
    The Wistar Institute, 3601 Spruce St, Philadelphia, Pennsylvania 19104, USA
    Nat Genet 38:468-73. 2006
    ..study, we show that clonal diversity measures adapted from ecology and evolution can predict progression to adenocarcinoma in the premalignant condition known as Barrett's esophagus, even when controlling for established genetic risk ..
  37. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors ..
  38. doi A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population
    Kouya Shiraishi
    Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
    Nat Genet 44:900-3. 2012
    Lung adenocarcinoma is the most common histological type of lung cancer, and its incidence is increasing worldwide...
  39. ncbi Chemotherapy with preoperative radiotherapy in rectal cancer
    Jean Francois Bosset
    Department of Radiation Therapy, University of Franche Comte, Besancon, France
    N Engl J Med 355:1114-23. 2006
    ..Preoperative radiotherapy is recommended for selected patients with rectal cancer. We evaluated the addition of chemotherapy to preoperative radiotherapy and the use of postoperative chemotherapy in the treatment of rectal cancer...
  40. pmc A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma
    Maria Teresa Landi
    Division of Cancer Epidemiology, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Am J Hum Genet 85:679-91. 2009
    ..In analyses by histology, rs2736100 (TERT), on chromosome 5p15.33, was associated with risk of adenocarcinoma (odds ratio [OR]=1.23, 95% confidence interval [CI]=1.13-1.33, p=3...
  41. ncbi Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction
    J S Macdonald
    St Vincent's Comprehensive Cancer Center, New York, USA
    N Engl J Med 345:725-30. 2001
    BACKGROUND: Surgical resection of adenocarcinoma of the stomach is curative in less than 40 percent of cases...
  42. pmc Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e73. 2005
    ..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance...
  43. doi Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium
    Toshiro Sato
    Hubrecht Institute, KNAW and University Medical Centre Utrecht, Utrecht, The Netherlands
    Gastroenterology 141:1762-72. 2011
    ..We have adapted the culture conditions to grow similar epithelial organoids from mouse colon and human small intestine and colon...
  44. ncbi Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    ..We compared such treatment with docetaxel plus prednisone in men with this disease...
  45. pmc Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
    Sian Jones
    Sol Goldman Pancreatic Cancer Research Center, Ludwig Center and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1801-6. 2008
    ..Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis...
  46. pmc Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
    E L Jackson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Genes Dev 15:3243-8. 2001
    b>Adenocarcinoma of the lung is the most common form of lung cancer, but the cell of origin and the stages of progression of this tumor type are not well understood...
  47. pmc MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival
    Ewy A Mathe
    Laboratory of Human Carcinogenesis, National Cancer Institute NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:6192-200. 2009
    ..established the role of miRNAs in esophageal carcinoma, a comprehensive multicenter study investigating different histologic types, including squamous cell carcinoma (SCC) and adenocarcinoma with or without Barrett's, is still lacking.
  48. doi Comprehensive histologic analysis of ALK-rearranged lung carcinomas
    Akihiko Yoshida
    Pathology and Clinical Laboratory Division, National Cancer Center Hospital, Tokyo, Japan
    Am J Surg Pathol 35:1226-34. 2011
    ..All 54 cases showed at least a focal adenocarcinoma component, and 3 and 2 cases had additional squamous and sarcomatoid differentiation, respectively...
  49. pmc Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling
    James P Sullivan
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Cancer Res 70:9937-48. 2010
    ..Therapeutic targeting of the Notch pathway reduces this ALDH(+) component, implicating Notch signaling in lung cancer stem cell maintenance...
  50. doi Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation
    Shih Hwa Chiou
    Institute of Pharmacology, National Yang Ming University, Taipei, Taiwan
    Cancer Res 70:10433-44. 2010
    ..and quantitative real-time PCR analysis showed a parallel, elevated expression of Oct4 and Nanog in lung adenocarcinoma (LAC)...
  51. ncbi Classification of colorectal cancer based on correlation of clinical, morphological and molecular features
    J R Jass
    Department of Pathology, McGill University, Montreal, Canada
    Histopathology 50:113-30. 2007
    ..This approach to the classification of CRC should accelerate understanding of causation and will impact on clinical management in the areas of both prevention and treatment...
  52. ncbi Lung cancer in never smokers--a different disease
    Sophie Sun
    Division of Haematology and Oncology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Nat Rev Cancer 7:778-90. 2007
    ..This Review summarizes our current knowledge of this unique and poorly understood disease...
  53. doi KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
    Kengo Takeuchi
    The Cancer Institute, Japanese Foundation for Cancer Research, Japan
    Clin Cancer Res 15:3143-9. 2009
    ..The sensitivity of EML4-ALK detection by immunohistochemistry should be increased adequately...
  54. pmc Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion
    Adam J Bass
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 43:964-8. 2011
    Prior studies have identified recurrent oncogenic mutations in colorectal adenocarcinoma and have surveyed exons of protein-coding genes for mutations in 11 affected individuals...
  55. ncbi MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
    I A Asangani
    Department of Experimental Surgery and Molecular Oncology of Solid Tumors, Medical Faculty Mannheim, University of Heidelberg, Germany
    Oncogene 27:2128-36. 2008
    ..This is the first study to show that Pdcd4 is negatively regulated by miR-21. Furthermore, it is the first report to demonstrate that miR-21 induces invasion/intravasation/metastasis...
  56. pmc Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  57. doi Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes
    Zhi Jiang Zang
    Cellular and Molecular Research, National Cancer Centre, Singapore
    Nat Genet 44:570-4. 2012
    ..In functional assays, we observed both FAT4 and ARID1A to exert tumor-suppressor activity. Somatic inactivation of FAT4 and ARID1A may thus be key tumorigenic events in a subset of gastric cancers...
  58. doi Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations
    Daiki Miki
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    Nat Genet 42:893-6. 2010
    ..To identify genetic factors that modify the risk of lung adenocarcinoma, we conducted a genome-wide association study in a Japanese cohort, with replication in two independent ..
  59. doi Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
    David Cunningham
    Royal Marsden National HealthService NHS Foundation Trust, London and Surrey, United Kingdom
    J Clin Oncol 27:5513-8. 2009
    ..This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP)...
  60. doi Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma
    Danit Lebanony
    Rosetta Genomics Ltd, 10 Plaut St, Rehovot 76706, Israel
    J Clin Oncol 27:2030-7. 2009
    ..In this study, we set out to identify specific microRNA biomarkers for the identification of squamous cell carcinoma, and to use such markers for the development of a standardized assay...
  61. doi MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
    Douglas D Taylor
    Department of Obstetrics, Gynecology, and Women s Health, University of Louisville School of Medicine, Louisville, KY 40202, USA
    Gynecol Oncol 110:13-21. 2008
    ..Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes...
  62. ncbi Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
    M Tanner
    Laboratory of Cancer Biology, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN 33101 Tampere, Finland
    Ann Oncol 16:273-8. 2005
    ..HER-2/neu gene amplification has predictive value in breast cancer patients responding to trastuzumab. We wanted to investigate the frequency and clinical significance of HER-2/neu amplification in gastric carcinoma...
  63. ncbi Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial
    Antonio M Lacy
    Department of Surgery, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, 08036 Barcelona, Spain
    Lancet 359:2224-9. 2002
    ..Our study aimed to compare efficacy of LAC and open colectomy (OC) for treatment of non-metastatic colon cancer in terms of tumour recurrence and survival...
  64. ncbi Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203
    Jean Pierre Gerard
    Centre Antoine Lacassagne, Radiotherapy Department, Nice, France
    J Clin Oncol 24:4620-5. 2006
    ..In 1992, preoperative radiotherapy was considered in France as the standard treatment for T3-4 rectal cancers. The present randomized trial compares preoperative radiotherapy with chemoradiotherapy...
  65. pmc A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing
    Young Seok Ju
    Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Korea
    Genome Res 22:436-45. 2012
    ..parallel whole-genome and transcriptome sequencing for cancer and paired normal tissue of a 33-yr-old lung adenocarcinoma patient, who is a never-smoker and has no familial cancer history...
  66. doi First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung
    Ji Youn Han
    National Cancer Center, Goyang, Republic of Korea
    J Clin Oncol 30:1122-8. 2012
    Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs)...
  67. doi Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer
    Hiromi Sakamoto
    Nat Genet 40:730-40. 2008
    ..90, 95% CI = 1.56-2.33, P = 8.01 x 10(-11)). The polymorphism of the PSCA gene, which is possibly involved in regulating gastric epithelial-cell proliferation, influences susceptibility to diffuse-type gastric cancer...
  68. ncbi Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
    C Almoguera
    Department of Biochemistry, State University of New York, Stony Brook 11794
    Cell 53:549-54. 1988
    ..We conclude from these results that c-K-ras somatic mutational activation is a critical event in the oncogenesis of most, if not all, human cancers of the exocrine pancreas...
  69. doi Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
    Seiji Yano
    Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan
    Cancer Res 68:9479-87. 2008
    ..showed that hepatocyte growth factor (HGF), a ligand of MET oncoprotein, induces gefitinib resistance of lung adenocarcinoma cells with EGFR-activating mutations by restoring the phosphatidylinositol 3-kinase/Akt signaling pathway via ..
  70. doi Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Clin Oncol 28:1547-53. 2010
    Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage.
  71. pmc EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
    William Pao
    Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 101:13306-11. 2004
    ..Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity...
  72. doi KIF5B-RET fusions in lung adenocarcinoma
    Takashi Kohno
    Division of Genome Biology, National Cancer Center Research Institute, Chuo Ku, Tokyo, Japan
    Nat Med 18:375-7. 2012
    ....
  73. doi The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends
    A P Thrift
    Population Health Department, Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    Ann Oncol 23:3155-62. 2012
    During the past four decades, the incidence of esophageal adenocarcinoma (EAC) has increased markedly in Western populations. Recent reports have suggested that the rate of increase has slowed or plateaued.
  74. pmc A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma
    Christian C Abnet
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Nat Genet 42:764-7. 2010
    ..19 x 10(-15); OR = 1.57), and for those in the noncardia stomach it was absent (P = 0.44; OR = 1.05). Our findings at 10q23 could provide insight into the high incidence of both cancers in China...
  75. doi Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
    Ilfet Songun
    Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
    Lancet Oncol 11:439-49. 2010
    ..clinical trial, was undertaken to compare D2 with D1 lymphadenectomy in patients with resectable primary adenocarcinoma of the stomach...
  76. doi Assessment of a HER2 scoring system for gastric cancer: results from a validation study
    M Hofmann
    Institute of Pathology, Klinikum Kassel, Kassel, Germany
    Histopathology 52:797-805. 2008
    ..The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrollment in a trial of trastuzumab (Herceptin) in advanced metastatic gastric cancer...
  77. doi Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
    J Ying
    Department of Pathology, Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    Ann Oncol 24:2589-93. 2013
    To evaluate the diagnostic value of a novel fully automated immunohistochemistry (IHC) assay for detection of anaplastic lymphoma kinase (ALK) fusion in a large number of ALK-positive lung adenocarcinoma (ADC) patients.
  78. ncbi MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma
    A E Szafranska
    Asuragen Inc, Austin, Woodward, TX 78744, USA
    Oncogene 26:4442-52. 2007
    Pancreatic ductal adenocarcinoma (PDAC) is known for its very poor overall prognosis. Accurate early diagnosis and new therapeutic modalities are therefore urgently needed...
  79. doi Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction
    Michael Stahl
    Department of Medical Oncology and Hematology, Kliniken Essen Mitte, Henricistr 92, D 45136 Essen, Germany
    J Clin Oncol 27:851-6. 2009
    Preoperative chemotherapy is an accepted standard in the treatment of localized esophagogastric adenocarcinoma. Adding radiation therapy to preoperative chemotherapy appears promising, but its definitive value remains unknown.
  80. ncbi Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
    Malcolm J Moore
    Division of Medical Oncology, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 25:1960-6. 2007
    ..We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer...
  81. pmc Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
    Suhaida A Selamat
    Department of Surgery, Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9176, USA
    Genome Res 22:1197-211. 2012
    Lung cancer is the leading cause of cancer death worldwide, and adenocarcinoma is its most common histological subtype...
  82. doi Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
    Nigel B Jamieson
    West of Scotland Pancreatic Unit and Department of Pathology, Glasgow Royal Infirmary, Alexandra Parade, Glasgow, United Kingdom
    Clin Cancer Res 17:3316-31. 2011
    The management of pancreatic ductal adenocarcinoma (PDAC) continues to present a great challenge particularly with regard to prediction of outcome following pancreaticoduodenectomy...
  83. doi Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, 1 1 Kanokoden, Chikusa ku, Nagoya 464 8681, Japan
    J Clin Oncol 29:2972-7. 2011
    ..Some studies have shown that epidermal growth factor receptor (EGFR) mutations can be heterogeneously distributed in individual tumors. In this study, we re-evaluated the distribution of EGFR mutations within tumors...
  84. doi SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity
    Munehide Nakatsugawa
    Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
    Lab Invest 91:1796-804. 2011
    ..the functions of SOX2 in cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) derived from human lung adenocarcinoma. Human lung CSCs/CICs were isolated as higher tumorigenic side population (SP) cells using Hoechst 33342 dye ..
  85. pmc Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial
    Patrick J Loehrer
    Indiana University Melvin and Bren Simon Cancer Center, 980 West Walnut St, Suite C528, Indianapolis, IN 46202, USA
    J Clin Oncol 29:4105-12. 2011
    ..The purpose of this trial was to evaluate the role of radiation therapy with concurrent gemcitabine (GEM) compared with GEM alone in patients with localized unresectable pancreatic cancer...
  86. pmc MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
    Jochen K Lennerz
    Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 29:4803-10. 2011
    ..We examined a GEC cohort with follow-up and reported the clinical response of four additional patients with MET-amplified tumors to the small molecule inhibitor crizotinib as part of an expanded phase I cohort study...
  87. ncbi A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study
    Henry M Keys
    Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA
    Gynecol Oncol 92:744-51. 2004
    Despite their low risk for recurrence, many women with endometrial adenocarcinoma receive postoperative radiation therapy (RT)...
  88. ncbi Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
    Alexander Arlt
    1Laboratory of Molecular Gastroenterology and Hepatology, 1st Department of Medicine, University of Kiel, Germany
    Oncogene 22:3243-51. 2003
    ....
  89. pmc Suppression of lung adenocarcinoma progression by Nkx2-1
    Monte M Winslow
    David H Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Nature 473:101-4. 2011
    ..Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using ..
  90. ncbi The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence
    Heiko Pohl
    VA Outcomes Group 111B, Department of Veterans Affairs Medical Center, White River Junction, VT 0500, USA
    J Natl Cancer Inst 97:142-6. 2005
    The incidence of esophageal adenocarcinoma is rising dramatically...
  91. ncbi Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung
    Mitch Raponi
    Molecular Diagnostics, Veridex LLC a Johnson and Johnson Company, 3210 Merryfriend Row, San Diego, CA 92121, USA
    Cancer Res 66:7466-72. 2006
    Non-small-cell lung cancers (NSCLC) compose 80% of all lung carcinomas with squamous cell carcinomas (SCC) and adenocarcinoma representing the majority of these tumors...
  92. pmc Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09
    Anthony L Zietman
    Department of Radiation Oncology, Cox 3, Massachusetts General Hospital, Boston MA 02114, USA
    J Clin Oncol 28:1106-11. 2010
    ..This was achieved without an increase in grade >/= 3 late urinary or rectal morbidity...
  93. pmc Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    Philip A Philip
    Wayne State University, Karmanos Cancer Institute, GI Oncology, Detroit, MI 48201, USA
    J Clin Oncol 28:3605-10. 2010
    ..This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor...
  94. pmc Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma
    Etienne Meylan
    Koch Institute for Integrative Cancer Research, and Department of Biology, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
    Nature 462:104-7. 2009
    ..Here we show that the NF-kappaB pathway is required for the development of tumours in a mouse model of lung adenocarcinoma. Concomitant loss of p53 (also known as Trp53) and expression of oncogenic Kras(G12D) resulted in NF-kappaB ..
  95. doi Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma
    Cheryl A Adackapara
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Histopathology 63:187-93. 2013
    ..A BRAF V600E-specific antibody has recently become commercially available. The aim of this study was to determine whether immunohistochemistry can predict BRAF mutations in CRC...
  96. pmc The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells
    Vikas Sehdev
    Department of Surgery, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 2215 Garland Avenue, Nashville, TN 37232, USA
    Mol Cancer Ther 11:763-74. 2012
    ..01). Immunohistochemical analysis showed overexpression of AURKA in more than two-thirds of esophageal adenocarcinoma tissue samples (92 of 132, 70%; P < 0.001)...
  97. pmc Dachshund binds p53 to block the growth of lung adenocarcinoma cells
    Ke Chen
    Departments of Cancer Biology, Stem Cell Biology and Regenerative Medicine, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Cancer Res 73:3262-74. 2013
    ..Expression of the stem cell factor SOX2 was repressed by DACH1, and SOX2 expression was inversely correlated with DACH1 in NSCLC. We conclude that DACH1 binds p53 to inhibit NSCLC cellular growth...
  98. doi Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
    Takayuki Fukui
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Lung Cancer 77:319-25. 2012
    ..We explored the EML4-ALK gene in a relatively large cohort and reviewed the clinicoradiologic background of the patients...
  99. pmc Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma
    Catherine Duggan
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Clin Gastroenterol Hepatol 11:934-43. 2013
    Individuals with Barrett's esophagus (BE) have an increased risk of developing esophageal adenocarcinoma (EA). Obesity contributes to the development of BE and its progression to cancer...
  100. pmc Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers
    Jin Sung Jang
    Division of Pulmonary and Critical Care Medicine, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 18:3658-67. 2012
    ..miRNA plays an important role in human disease and cancer. We seek to investigate the expression status, clinical relevance, and functional role of miRNA in non-small cell lung cancer...
  101. pmc miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma
    Andrea L Kasinski
    Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, Connecticut 06520, USA
    Cancer Res 72:5576-87. 2012
    ..These data support the use of miR-34 as a lung tumor-preventative and tumor-static agent...

Research Grants77

  1. Role of SAMe on UBC9 and sumolyation in liver cancer and alcoholic liver injury
    Maria Lauda Tomasi; Fiscal Year: 2012
    ..Furthermore, UBC9 is overexpressed in several malignancies, such as lung adenocarcinoma, ovarian carcinoma, and melanoma...
  2. Prostate cancer chemoprevention by penta-galloyl-glucose
    Junxuan Lu; Fiscal Year: 2013
    ..Aim 4. To establish the chemopreventive efficacy of PGG against the autochthonous transgenic adenocarcinoma mouse prostate (TRAMP) model of primary prostate carcinogenesis. Aim 5...
  3. Mechanistic Studies on Prostate Cancer Prevention by Gugulipid
    Dong Xiao; Fiscal Year: 2013
    ..five weeks of age for 20 weeks, significantly inhibits prostate cancer incidence and progression in transgenic adenocarcinoma of mouse prostate (TRAMP) mice without causing weight loss or any other side effects...
  4. Folate Status, Genomic Uracil, and the Balance of Base Excision Repair Activity
    Michael D Wyatt; Fiscal Year: 2011
    ..instability, which is procarcinogenic to normal epithelial cells and anticarcinogenic to established adenocarcinoma cells...
  5. Stat3 Downstream Genes as Lung Adenocarcinoma Biomarkers
    Cong Yan; Fiscal Year: 2013
    ..provided by applicant): The long-term goal of this work is to identify secretory protein biomarkers for lung adenocarcinoma diagnosis and prognosis in animals and in humans...
  6. The role of LKB1 in the maintenance of genomic stability.
    Zhi Xiang Xu; Fiscal Year: 2013
    ..Inactivating mutations in LKB1 are also found in cancer patients without PJS, including sporadic lung adenocarcinoma (common), ovarian cancer, breast cancer, pancreatic cancer, and biliary adenocarcinoma (rare)...
  7. Modulation of cancer prevention by social stress
    Hildegard M Schuller; Fiscal Year: 2010
    ..We have shown that two of the most common and most deadly cancers, small airway-derived pulmonary adenocarcinoma (PAC) and pancreatic ductal adenocarcinoma (PDAC) are stimulated in vitro and in vivo by cAMP-dependent ..
  8. NADPH oxidase-associated transition from Barrett's esophagus to adenocarcinoma
    Weibiao Cao; Fiscal Year: 2013
    ..esophagus (BE), which is associated with nearly a 30-125-fold increased risk for the development of esophageal adenocarcinoma (EA). The mechanism of progression from BE to dysplasia and to EA is unknown...
  9. Endocrine Targets for Prevention of Lung Cancer
    Robert M Bigsby; Fiscal Year: 2012
    ..in non-small cell lung cancer and that ovarian hormones play a role by promoting tumor growth, particularly in adenocarcinoma. Tumor promoter action of hormones is likely to be most effective early in the carcinogenic process...
  10. Delivery issues in lung cancer CNS metastases
    Edward A Neuwelt; Fiscal Year: 2013
    ..non-small cell lung cancer (NSCLC) variants H460 large cell carcinoma, H520 squamous cell carcinoma, and A549 adenocarcinoma. Treatment paradigms will be whole brain radiation therapy with or without temozolomide chemotherapy, and ..
  11. Biomarker Reference Laboratory, EDRN
    William E Grizzle; Fiscal Year: 2010
    ..Study of the use of SELDI-TOF-MS to identify protein signatures in serum that predict the presence of adenocarcinoma of the prostate...
  12. Tea Polyphenols in Chemoprevention of Prostate Cancer
    SUSANNE MARGARETE HENNING; Fiscal Year: 2011
    ..Bax, Bcl-2, NFkB and concentration of 8-hydroxydeoxyguanosine in sections of equal morphological changes of adenocarcinoma in the human prostate...
  13. Amoeboid Membrane Dynamics in Prostate Cancer
    Michael R Freeman; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Prostate adenocarcinoma (PCa) is a leading cause of death from cancer and there is no effective treatment for "castration-resistant" disease...
  14. Mouse models for esophageal Cox-2 oxidative stress and DNA damage
    John P Lynch; Fiscal Year: 2013
    ..in response to chronic acid and bile reflux and is an important risk factor for the development of esophageal adenocarcinoma (EAC)...
  15. Cx43 phosphorylation modulates Kras mediated pancreas cancer progression
    Paul D Lampe; Fiscal Year: 2012
    ..by applicant): With an annual incidence and mortality of ~38,000 people, pancreas cancer or pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States...
  16. PET TUMOR AND PROLIFERATION IMAGING VIA CATIONIC AMINO ACID TRANSPORT
    JONATHAN EDWARD MCCONATHY; Fiscal Year: 2013
    ..of transport will be determined in vitro using rat 9L gliosarcoma, mouse DBT glioma and mouse mammary adenocarcinoma 66 cell lines...
  17. Prevention of Esophageal Cancer with Berries
    Gary Stoner; Fiscal Year: 2013
    ..There are two histologic types of esophageal cancer;squamous cell carcinoma (SCC) and adenocarcinoma. SCC is by far the most common type worldwide, accounting for about 90% of all esophageal cancer...
  18. Mitochondrial Metabolism and ROS Regulate Lung Cancer
    Navdeep S Chandel; Fiscal Year: 2013
    ..However, it is not known if inhibition of GPT2 would attenuate lung adenocarcinoma in vivo or if GPT2 is dispensable for normal tissues in the adult mouse...
  19. Structure and function of Helicobacter pylori VacA
    Timothy L Cover; Fiscal Year: 2013
    ..pylori-infected persons remain asymptomatic, potentially serious sequelae of infection include gastric adenocarcinoma, duodenal ulceration, gastric ulceration, and gastric lymphoma...
  20. COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
    Zhenfeng Duan; Fiscal Year: 2013
    ..efficacy, cytotoxicity and apoptotic activity in wild-type (SK0V3) mdr-1 positive (SKOVSTR) human ovarian adenocarcinoma and wild- type (NIH-H69) and mrp-1 positive (NIH-H69AR) small cell lung adenocarcinoma cells;(3) selection of "..
  21. Timing of Exposure to Selenium and Isoflavones and Prostate Cancer Prevention
    EDWIN DOUGLAS LEPHART; Fiscal Year: 2010
    ..isoflavones, individually and in combination, will inhibit progression of prostate cancer in TRAMP (TRansgenic Adenocarcinoma of Mouse Prostate) mice, dependent on the timing of dietary intervention...
  22. PPAR gamma Agonists for Lung Cancer Chemoprevention
    Robert Keith; Fiscal Year: 2013
    ..transgenic mice with selective pulmonary PGIS over-expression are chemoprotected in several distinct murine adenocarcinoma models (including both chemical and tobacco-smoke exposure)...
  23. Self-Determination Theory and Lifestyle Behaviors in Barrett's Esophagus Patients
    HODA J BADR; Fiscal Year: 2010
    ..chronic gastroesophageal reflux disease (GERD) and is a major risk factor for the development of esophageal adenocarcinoma (EAC)...
  24. OPTICAL BIOPSY USING OPTICAL COHERENCE TOMOGRAPHY
    James G Fujimoto; Fiscal Year: 2012
    ..We will investigate upper and lower Gl tract pathologies including Barrett's esophagus, dysplasia, and adenocarcinoma, as well as dysplasia and adenocarcinoma in inflammatory bowel disease...
  25. Targeting Glucose Metabolism in Cancer
    Sucheta Telang; Fiscal Year: 2013
    ..We found that hypoxic exposure of K-rasG12S+ A549 lung adenocarcinoma cells and introduction of H-rasG12V into immortalized human bronchial epithelial cells increased PFKFB4 mRNA ..
  26. Function of the Ras Related Ral Protein
    LARRY FEIG; Fiscal Year: 2013
    ..represent new drug targets to block the formation of not only skin squamous carcinoma but also breast adenocarcinoma. PUBLIC HEALTH RELEVANCE: There is abundant evidence that the tissue microenvironment has a major effect on ..
  27. Role of the Sex Hormones and Insulin/IGF-Axes in Endometrial Cancer Recurrence
    Howard D Strickler; Fiscal Year: 2012
    ..Two of the strongest risk factors for endometrioid adenocarcinoma (EA), the most common form of endometrial cancer, are estrogen exposure and obesity...
  28. ASCORBATE-INDUCED RADIOSENSITIZATION IN PANCREATIC CANCER
    Joseph J Cullen; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in the United States and is increasing in incidence;the prognosis remains dismal...
  29. Metabolic Syndrome, Fatty Acid Synthesis and Prostate Cancer
    Massimo Loda; Fiscal Year: 2012
    ..human prostate epithelial cells and as a transgene directed to the murine prostate results in invasive adenocarcinoma and prostatic intraepithelial neoplasia, respectively...
  30. Mechanisms of H. pylori-Induced Hypochlorhydria
    Adam J Smolka; Fiscal Year: 2010
    ..gastritis and transient hypochlorhydria which may progress to atrophic gastritis and eventually gastric adenocarcinoma. Acute hypochlorhydria is critical for initial establishment of infection, but its mechanistic basis and its ..
  31. Regulation and Role of Ornithine Decarboxylase in Cell Proliferation and Cancer
    John L Cleveland; Fiscal Year: 2013
    ..Using validated Myc-driven mouse models of B cell lymphoma and mammary adenocarcinoma, and of K-Ras-directed lung adenocarcinoma, we will test the roles of Odc in oncogene-driven proliferation and ..
  32. Flavonoids, esophageal/gastric cardia adenocarcinoma and Barretts Esophagus Risk
    Marilie D Gammon; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Flavonoids, esophageal/gastric cardia adenocarcinoma and Barrett's esophagus risk ABSTRACT...
  33. Genetic Instability &Risk for Esophageal Carcinoma
    Xifeng Wu; Fiscal Year: 2012
    ..using a panel of markers including telomere dysfunction and DNA damage/or repair as predictors of esophageal adenocarcinoma (EAC) risk...
  34. Dual Modality System for Imaging Colon Cancer in Mice
    Jennifer Kehlet Barton; Fiscal Year: 2013
    ..We will perform four studies: a) How do ACF and gastrointestinal neoplasias progress to adenoma and/or adenocarcinoma? b) Can treatment with [unreadable]-difluoromethylornithine (DFMO) and/or sulindac regress adenoma and prevent ..
  35. ELUCIDATING THE FUNCTION OF MATRIPTASE-ACTIVATED PDGF D IN BONE METASTATIC PROSTA
    ABDO JAMAL NAJY; Fiscal Year: 2012
    ..This adenocarcinoma metastasizes to the bone in 90% of cases resulting in the disruption of the bone microenvironment and causing ..
  36. Oxyntic Atrophy and Novel Gastric Lineages
    JAMES RICHARD GOLDENRING; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Gastric adenocarcinoma remains the second most common cause of cancer-related death worldwide...
  37. Discovery of Novel Antitumor Agents Effective Against Pancreatic Cancer
    Amy E Wright; Fiscal Year: 2012
    ..dependent growth in pancreatic cancer cells, block tumor cell migration and re-sensitize the ASPC-1 pancreatic adenocarcinoma cancer cell line to TRAIL induced apoptosis...
  38. The Role of de novo Cytosine DNA Methyltransferases 3a &3b in Gene Methylation
    Ivo Teneng; Fiscal Year: 2013
    ..of altered genes and microRNAs (miRs) and the pathways they regulate that interact in early premalignancy of adenocarcinoma are largely unknown...
  39. Aldo-Keto Reductases and PAH Metabolism/Activation
    Trevor M Penning; Fiscal Year: 2013
    ..In human lung adenocarcinoma (A549) cells this pathway results in the production of reactive oxygen species (ROS) and formation of the ..
  40. Established Investigator Award in Cancer Prevention and Control
    Thomas L Vaughan; Fiscal Year: 2013
    ..30% FTE) to continue to pursue key research questions related to the etiology and prevention of esophageal adenocarcinoma (EA), a cancer that has undergone a remarkable increase in incidence (6-fold overall, and 10-fold among white ..
  41. Novel Strategy for Lung Cancer Treatment Using IGF-1R Inhibitor
    Ho Young Lee; Fiscal Year: 2013
    ..we propose to: 1) assess the ability of NNK to stimulate development, growth and progression of pulmonary adenocarcinoma in mouse models with lung-specific overexpression of IGF-1R, with or without concomitant increase in Src or c-..
  42. Comprehensive Phenotypic Comparison of Normal and Cancer Stem Cells
    RAMESH A contact SHIVDASANI; Fiscal Year: 2010
    ..similarities and differences between normal and cancer stem cells isolated from normal intestine/colorectal adenocarcinoma, neural stem cells/glioblastoma multiforme (GBM) and hematopoietic stem cells/acute myelogenous leukemia (AML)...
  43. Lysophosphatidic Acid in Oncogenesis
    Xianjun Fang; Fiscal Year: 2010
    ..The tumors include malignant lymphoma, lung adenocarcinoma, high-grade sarcoma, leiomyosarcoma, plasmacytoma and pilomatrixoma...
  44. Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo
    Jie Wu; Fiscal Year: 2013
    ..and the RET tyrosine kinase (KIF5B-RET) is the most recent genetic alternation identified in human lung adenocarcinoma. Preclinical models of KIF5B-RET have been limited to xenografts of transfected NIH3T3 fibroblasts and Ba/F3 ..
  45. Curcumin and chemoprevention of H. pylori-associated gastric carcinogenesis
    Rupesh Chaturvedi; Fiscal Year: 2013
    ..pylori is a Gram-negative bacterium that causes chronic gastritis, peptic ulcers, and gastric cancer. Gastric adenocarcinoma is the second leading cause of cancer-related death worldwide and H...
  46. GABA-B-R-mediated prevention of pancreatic cancer
    Hildegard M Schuller; Fiscal Year: 2013
    Project Summary. Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality with near 100% of the victims succumbing within 6 month of diagnosis...
  47. Notch-1 and IGF-1 crosstalk: new therapeutic strategies for NSCLC
    Maurizio Bocchetta; Fiscal Year: 2013
    ..Among the three major histological types of NSCLC, adenocarcinoma of the lung (ACL) is the most prevalent, and its incidence is steadily raising...
  48. Validation of MRI Microvascular Biomarkers in Pancreatic Cancer with Magnetic Nan
    ALEXANDER RAMOS GUIMARAES; Fiscal Year: 2013
    ..nanoparticles (MNP) to study and quantify the unique microvascular characteristics of pancreatic ductal adenocarcinoma (PDAC)...
  49. Inhibition of Reflux-Induced Esophageal Adenocarcinoma by Proanthocyanidins
    Laura A Kresty; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Esophageal adenocarcinoma (EAC) rates have increased 500% over the last three decades resulting in EAC being identified as the fastest increasing of all cancer types in the US...
  50. A high-throughput screen for small-molecule antagonists of Gli function
    James K Chen; Fiscal Year: 2012
    ..in mouse models of Hh pathway-dependent tumors, such as basal cell carcinoma, medulloblastoma, pancreatic adenocarcinoma, and prostate cancer...
  51. Targeting Adipocyte Lipases to Treat Pancreatic Cancer-Associated Cachexia
    Enrique Saez; Fiscal Year: 2013
    ..a progressive atrophy of adipose tissue and skeletal muscle that occurs in more than 85% of pancreatic ductal adenocarcinoma (PDAC) patients...
  52. PROCESSED ANTIGEN CHARACTERIZATION BY MASS SPECTROMETRY
    Donald F Hunt; Fiscal Year: 2012
    ..make it possible to extend adoptive T-cell therapy to a number of other cancers including acute myeloid leukemia, chronic lymphocytic leukemia, pancreatic-,colorectal- and heptocellullar- adenocarcinoma and renal cancer.
  53. METABOLITE BIOIMARKERS IN THE DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA
    Thomas L Vaughan; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The incidence of esophageal adenocarcinoma (EA) in the US has increased 300% over recent decades while median survival remains an abysmal 10 months...
  54. Biomarkers for Esophageal Cancer Progression and Prognosis
    Tony E Godfrey; Fiscal Year: 2012
    ..by applicant): Esophageal cancer occurs in two major histologic types;squamous cell carcinoma (SCC) and adenocarcinoma (EA) both of which have an extremely poor prognosis...
  55. NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)
    Elaine R Mardis; Fiscal Year: 2013
    ..The use ofthis pipeline has resulted in an expansion of our understanding of mutations occurring in lung adenocarcinoma, acute myeloid leukemia, and glioblastoma multiforme...
  56. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St
    Christopher Horvath; Fiscal Year: 2013
    ..in "triple-negative" (TNBC;estrogen, progesterone and Her2 receptor-negative) breast cancer (BCa), pancreatic adenocarcinoma (PCa) and glioblastoma multiforme (GBM) primary tumors and respective cell lines (MDA- MB-468, Panc-1, U87)...
  57. Mechanisms of RelA Activation in Cancer
    Paul J Chiao; Fiscal Year: 2013
    Pancreatic adenocarcinoma is the fourth leading cause of adult cancer mortality in the United States. The five-year survival rate continues at 1-3% and the median survival after diagnosis is less than six months...
  58. The GABA-B receptor is a novel drug target for pancreatic cancer
    Hildegard M Schuller; Fiscal Year: 2012
    Project Summary. Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in Western countries and smoking, diabetes, and pancreatitis are risk factors...
  59. Predictors of Progression from Barrett's Esophagus to esophageal adenocarcinoma
    Brian J Reid; Fiscal Year: 2010
    ..of experience investigating Barrett's esophagus (BE), the only established precursor to esophageal adenocarcinoma (EA), a highly lethal malignancy whose incidence has increased more than 600% in three decades...
  60. Radiation Force Imaging of Prostate Cancer and Guidance of Biopsy Procedures
    Kathryn Radabaugh Nightingale; Fiscal Year: 2013
    ..screening mechanisms, prostate biopsies are performed to diagnose PCa, which depends upon the presence of adenocarcinoma in biopsy cores, with clinical significance being determined by the presence of 50% or more PCa tumor tissue ..
  61. Role of Acid in the Development of Barrett's Esophagus
    Stuart Jon Spechler; Fiscal Year: 2013
    ..reflux disease (GERD) contributes to the development of Barrett's esophagus and esophageal adenocarcinoma, a lethal tumor whose incidence has been rising at an alarming rate...
  62. Role of U19/Eaf2 in androgen-dependent prostate homeostasis
    Zhou Wang; Fiscal Year: 2013
    ..U19 knockout (KO) mice, which developed lymphoma, nepatocellular carcinoma, and poorly differentiated lung adenocarcinoma. This demonstrated that U19 is a tumor suppressor...
  63. Testing of novel anti-cancer compounds Curaxins against pancreatic cancer
    Katerina Gurova; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches...
  64. HISTOMETRIC ANALYSIS OF PREMALIGNANT ENDOMETRIAL LESIONS
    Francisco Garcia; Fiscal Year: 2003
    b>Adenocarcinoma of the endometrium is the most common gynecologic malignancy in the United States. It accounts for about 36,000 cases of invasive cancer each year and is among the top five neoplasms affecting women...
  65. Ultrasound guided site-specific gene delivery in prostate cancer
    Pier Paolo Claudio; Fiscal Year: 2010
    ..the progress of modern radiation techniques in largely improving the prognosis of patients with prostate adenocarcinoma, the maximum benefit that can be achieved with conventional radiation therapy has probably been reached...
  66. VIP AND EGF RECEPTORS IN NON-SMALL CELL LUNG CANCER
    Terry Moody; Fiscal Year: 1991
    ..are small cell lung cancer (SCLC), a neuroendocrine tumor which responds to chemo- and/or radiation therapy, adenocarcinoma, large cell carcinoma and squamous cell carcinoma...
  67. Foregut microbiome in development of esophageal adenocarcinoma
    Zhiheng Pei; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Esophageal adenocarcinoma (EA), the type of cancer linked to heartburn due to gastroesophageal reflux diseases (GERD), has increased six fold in the past 30 years, which cannot be explained by the ..
  68. Zinc-Based Early Detection of Prostate Cancer
    Christopher J Frederickson; Fiscal Year: 2010
    ..79, .92, and .99 for detecting biopsy-confirmed prostatic adenocarcinoma. Our test is non-invasive, requiring only a few drops of prostatic fluid obtained from the urethral meatus ..
  69. T Cell Initiated Gastric Pathology
    ROBINNA LORENZ; Fiscal Year: 2007
    ..world's population, is linked to gastric and duodenal ulcer disease, mucosal-associated lymphomas, and adenocarcinoma. Infection with H...
  70. Role of H. Pylori Infection in Esophageal Adenocarcinoma
    Kam Meng Tchou Wong; Fiscal Year: 2003
    ..pylori, especially the cagA+ strains, may protect against GERD, Barrett's esophagus and esophageal adenocarcinoma. The specific aims are as follows: 1...
  71. NADPH oxidases-associated transition from Barrett's esophagus to adenocarcinoma
    Weibiao Cao; Fiscal Year: 2007
    ..metaplasia of BE is associated with nearly a 30-125-fold increased risk for the development of esophageal adenocarcinoma. However, the mechanisms of progression from Barrett's esophagus (intestinal metaplasia) to dysplasia and ..
  72. The Prevalence of Barrett's Esophagus in Patients with *
    Blair Jobe; Fiscal Year: 2004
    The incidence of esophageal adenocarcinoma arising from Barrett's metaplasia has increased by 350% since 1970 and at the time of presentation, 50% of patients will have advanced disease with virtually no chance for cure...
  73. Mouse Model of Pancreatic Tumorigenesis with Dysregulation of mTOR
    Chongjuan Wei; Fiscal Year: 2009
    ..The overall goal of this proposal is to develop a mouse model for pancreatic adenocarcinoma with dysregulation of mTOR via deficiency in LKB1...
  74. Molecular epidemiology of cervical adenocarcinoma
    Hans Olov Adami; Fiscal Year: 2007
    The overall objective of this project is to improve the biologic understanding of adenocarcinoma and adenosquamous cancer of the cervix uteri (in the following referred to as adenocarcinoma) through investigation of its viral etiology, ..
  75. Combinational Chemoprevention of Esophageal Adenocarcin*
    Navtej Buttar; Fiscal Year: 2005
    Barrett's esophagus is a pre-malignant condition that predisposes to esophageal adenocarcinoma, which has one of the fastest rising incidence rates in the United States and has limited therapeutic options...
  76. microRNAs as novel Biomarkers for Pancreatic Ductal Adenocarcinoma
    Murray Korc; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Human pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in adults in the United States...
  77. Low-cost tethered capsule endoscope for screening for Barrett's esophagus
    Jason Dominitz; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The incidence of esophageal adenocarcinoma is rising faster than for any other cancer in the United States...